PRTA

Prothena Corporation plc

stock all instruments
+0.0
net board stance what this means
9.64
-1.8% · close 2026-09-08
+10% / +14% / +14%
1m / 3m / 12m
-165%
vs SPY since 2022-07-29
48%
of 52w range · -16.2% off high
hit rate as primary

Where we stand — 0 live ideas

No active idea holds this ticker. Anything below is history.

Where the winds are blowing

NET BOARD STANCE, LAST 47 EPISODES — rising = the besties are building this position, falling = abandoning it. Replayed from score_events; an idea counts from birth until its window closes.
PRICE VS SPY OVER THE SAME WINDOW, % — did the talk lead the tape or follow it?

Who's pushing which way

each voice's net push ON THIS TICKER — their most recent stance per idea × the idea's direction × strength, so supporting a bearish idea pushes down. Not conviction (that lives on the idea); this is direction of travel per person. what w= means

Chamath
Chamath w=0.84 equities
1 idea (0 live) · last heard E89
-2
pushes down
Friedberg
Friedberg w=0.87 equities
1 idea (0 live) · last heard E89
-3
pushes down

Track record on PRTA

No closed window has used this ticker as its primary play, so there is no scored record here yet. Adjacent plays are listed but never scored.

ideacallplayverdictRαclosed
📈 Alzheimer's amyloid hypothesis was built on fraud - the anti-amyloid franchise busts ▼ SHORT adjacent MISS -23.3% -36.0 2023-07-29

The tape — what was actually said

every capture on any idea holding PRTA, newest first · quotes verbatim, timestamps deep-link into the episode

Chamath Chamath support ×2 ▼ on 📈 Alzheimer's amyloid hypothesis was built on fraud - the anti-amyloid franchise busts E89 · 2022-07-29 ▶ 1:07:52
No, what I'm saying is the NIH budget per year for Alzheimer's and dementia is 1.9 billion. Half of it, if you look at the tags, if you just search the tags, half the money has gone into Alzheimer's disease, amyloid beta.
Friedberg Friedberg support ×3 ▼ on 📈 Alzheimer's amyloid hypothesis was built on fraud - the anti-amyloid franchise busts E89 · 2022-07-29 ▶ 1:08:55
And now the drug is in the market. Biogen gets approval and people start taking it. And we're seeing the data. It doesn't work. And no one wants to use it. So the market has collapsed and you kind of go back to the origin.